title: Helicobacter pylori resistance to clarithromycin in Reunion Island.
abstract: OBJECTIVE
  The increasing resistance of Helicobacter pylori to clarithromycin led to developing new eradication treatment regimens. The objective of our observational study was to determine the proportion of H. pylori strains resistant to clarithromycin in infected patients in Reunion Island and to suggest a first-line treatment in agreement with the local ecology.
  
  
  METHODS
  We included 200 patients who underwent esophagogastroduodenoscopy at the University Hospital of Saint-Pierre from February to July 2014. H. pylori was isolated from 73 patients.
  
  
  RESULTS
  A wild-type susceptibility profile to clarithromycin was observed in 64 isolates (87.7%) and nine isolates (12.3%) had a resistant mutation profile.
  
  
  CONCLUSIONS
  With a proportion of resistant strains below the critical threshold of 15%, physicians in Reunion Island may continue to prescribe the usual treatment regimen as a first-line option (clarithromycin, amoxicillin, and proton pump inhibitor for 14 days).
authors.affiliation: Laboratoire de bactériologie, virologie, parasitologie, centre hospitalier universitaire (CHU) de La Réunion, site GHSR, avenue François-Mitterrand, 97448 Saint-Pierre cedex, Reunion. Electronic address: nael.zemali@gmail.com.
authors.forename: N
authors.initials: N
authors.lastname: Zemali
authors.affiliation: Service de gastro-entérologie, CHU de La Réunion, 97410 Saint-Pierre, Reunion.
authors.forename: G
authors.initials: G
authors.lastname: Guillemot
authors.affiliation: Laboratoire de bactériologie, virologie, parasitologie, centre hospitalier universitaire (CHU) de La Réunion, site GHSR, avenue François-Mitterrand, 97448 Saint-Pierre cedex, Reunion.
authors.forename: J
authors.initials: J
authors.lastname: Jaubert
authors.affiliation: Laboratoire de bactériologie, virologie, parasitologie, centre hospitalier universitaire (CHU) de La Réunion, site GHSR, avenue François-Mitterrand, 97448 Saint-Pierre cedex, Reunion.
authors.forename: S
authors.initials: S
authors.lastname: Picot
authors.affiliation: Laboratoire de bactériologie, virologie, parasitologie, centre hospitalier universitaire (CHU) de La Réunion, site GHSR, avenue François-Mitterrand, 97448 Saint-Pierre cedex, Reunion.
authors.forename: E
authors.initials: E
authors.lastname: Thomas
authors.affiliation: Service de gastro-entérologie, CHU de La Réunion, 97410 Saint-Pierre, Reunion.
authors.forename: J P
authors.initials: JP
authors.lastname: Becquart
authors.affiliation: Service des maladies infectieuses, CHU de La Réunion, 97410 Saint-Pierre, Reunion.
authors.forename: G
authors.initials: G
authors.lastname: Camuset
authors.affiliation: Inserm centre d'investigation clinique (CIC1410), CHU de La Réunion, 97410 Saint-Pierre, Reunion; UMR PIMIT « processus infectieux en milieu insulaire tropical », Inserm 1187, CNRS 9192, IRD 249, université de La Réunion, CYROI, 97490 Sainte-Clotilde, Reunion.
authors.forename: P
authors.initials: P
authors.lastname: Gérardin
authors.affiliation: Laboratoire de bactériologie, virologie, parasitologie, centre hospitalier universitaire (CHU) de La Réunion, site GHSR, avenue François-Mitterrand, 97448 Saint-Pierre cedex, Reunion.
authors.forename: A
authors.initials: A
authors.lastname: Michault
authors.affiliation: Service de gastro-entérologie, CHU de La Réunion, 97410 Saint-Pierre, Reunion.
authors.forename: S
authors.initials: S
authors.lastname: Kwiatek
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000382:microbiology; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000494:pharmacology*; D004269:DNA, Bacterial / Q000235:genetics; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000453:epidemiology* / Q000209:etiology; D005748:Gastric Fundus / Q000382:microbiology; D005757:Gastritis, Atrophic / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D008679:Metaplasia; D009154:Mutation; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D011706:Pyloric Antrum / Q000382:microbiology; D017508:Reunion / Q000453:epidemiology; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D054328:Proton Pump Inhibitors; D000658:Amoxicillin; D017291:Clarithromycin
keywords: Clarithromycin resistance; Helicobacter pylori; La Réunion; Reunion Island; Résistance à la clarithromycine